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Summary
Neural tissue is entirely dependent on glucose for normal metabolic activity.
Since glucose stores in the brain and retina are negligible compared to
glucose demand, metabolism in these tissues is dependent upon adequate
glucose delivery from the systemic circulation. In the brain, the critical
interface for glucose transport is at the brain capillary endothelial cells which
comprise the blood±brain barrier (BBB). In the retina, transport occurs across
the retinal capillary endothelial cells of the inner blood±retinal barrier (BRB)
and the retinal pigment epithelium of the outer BRB. Because glucose
transport across these barriers is mediated exclusively by the sodium-
independent glucose transporter GLUT1, changes in endothelial glucose
transport and GLUT1 abundance in the barriers of the brain and retina may
have profound consequences on glucose delivery to these tissues and major
implications in the development of two major diabetic complications, namely
insulin-induced hypoglycemia and diabetic retinopathy. This review discusses
the regulation of brain and retinal glucose transport and glucose transporter
expression and considers the role of changes in glucose transporter expression
in the development of two of the most devastating complications of long-
standing diabetes mellitus and its management. Copyright # 1999 John
Wiley & Sons, Ltd.
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Introduction
Glucose is an essential metabolic substrate of all mammalian cells. Neural
tissue in particular, i.e. the brain and retina, is entirely dependent on glucose
under normal physiological conditions; however, access of neural tissues to a
steady supply of this nutrient is limited by two factors. First, glycogen stores
within neural tissue are either non-existent (e.g. brain) or inadequate to meet
basal metabolic demands (e.g. retina). This relative lack of local carbohydrate
stores results in a total dependence of neural tissue on delivery of glucose
from the circulation [1,2]. Second, each of these tissues possesses a barrier
between itself and its blood supply. In the brain, the presence of tight
junctions and a lack of fenestrations and pinocytotic activity characterize the
microvascular endothelial cells that comprise the BBB [3]. In the retina, two
barriers exist: the retinal capillary endothelial cells of the inner BRB, a
microvascular bed which is highly similar to that in the brain, and the retinal
pigment epithelium, a single layer of epithelial cells connected by tight
junctions which is located between the photoreceptor elements and the
choroid and is known as the outer BRB [4]. The presence of these barriers in
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neural tissue prevents the passive diffusion of glucose and
other blood-borne nutrients into the interstitial space
surrounding neural cells. Instead, glucose entry is
mediated by a speci®c, saturable, facilitated transport
process involving members of the sodium-independent
glucose transporter family (Table 1) [5,6]. The purpose of
the present review is to discuss glucose transport and
glucose transporter expression in the brain and retina and
their respective barriers. The review also discusses the
possible implications that changes in brain and retinal
glucose transport may have in the pathogenesis of a
complication associated with the treatment of diabetes
(iatrogenic hypoglycemia) and of one of the sequelae of
long-term hyperglycemia (diabetic retinopathy).
Five functional isoforms of the GLUT family have been
identi®ed and are numbered in the order of their
characterization. The various glucose transporter iso-
forms demonstrate, at least to a certain degree, tissue-
speci®c localization [5,6]. GLUT1, the ®rst isoform cloned
[7], is expressed in high density in the membranes of
human erythrocytes and is characteristically expressed in
blood±tissue barriers, such as the BBB, the blood±ocular
barriers and the blood±placental and blood±testis barriers
[2,8,9]. GLUT2 is expressed predominantly in the liver
and in pancreatic b-cells [10], where, functionally
coupled to hexokinase, it plays a role in sensing blood
glucose levels. GLUT3, originally isolated from a fetal
muscle cell line [11], has been identi®ed as the primary
glucose transporter in neural elements of the brain [12].
GLUT4 is expressed in high abundance in skeletal muscle
and fat [13,14], where it mediates insulin-sensitive
glucose transport, and GLUT5 is a fructose transporter
that is expressed predominantly in intestinal epithelium
[15]. The glucose transporter isoforms share 39±65%
amino acid sequence identity [5], and sequence com-
parisons between GLUT1 of various species reveal an
extremely high degree of conservation (>95%) [16],
thus emphasizing the critical and universal importance of
this transporter in cellular metabolism. Hydrophobicity
sequence analysis suggests that the GLUTs are arranged in
12 membrane-spanning regions [7]. In the case of
GLUT1, there is a single N-linked glycosylation site at
Asp45 in the ®rst extracellular loop [7]. Differential
glycosylation of this residue accounts for the different
molecular weights of GLUT1 in different cell types [17]
and may play a role in the subcellular localization of
GLUT1 [18,19]. The sodium-independent glucose trans-
porters mediate transport of glucose, glucose analogs
and other hexoses, with conformational speci®city (i.e.
transporting D- but not L-isomers) and different af®nities
for hexoses and glucose analogs. In addition, GLUT1 and
GLUT3 have been demonstrated to be responsible for the
transport of ascorbic acid [20], which, in brain capillary
endothelia, is transported in its oxidized form [21].
Glucose transport and glucose
transporters in brain
Glucose transport from the blood into the cytosol of the
neuronal elements of the brain occurs across several
membranes in series. Glucose ®rst enters the cytoplasm of
the endothelial cells of the BBB by transport across the
endothelial lumenal membrane via GLUT1. Subsequent
transport across the ablumenal membrane and into the
interstitial space is also mediated by the GLUT1 isoform.
Finally, glucose uptake into the cytosol of the neuronal
cells occurs via the neuronal GLUT3 glucose transporter
[22,23]. Cytochalasin-B binding studies suggest that the
density of glucose transporters on the BBB is 2±3 times
that on the neuronal cells [24]; however, because the
surface area of the BBB is less than 0.1% of that of the
neuronal elements of the brain, transport of glucose from
blood into brain is limited by its transport across the BBB
[1].
In studies using light microscopic immunohistochem-
istry and in situ hybridization of rat brain sections, GLUT1
is localized to the endothelia of the BBB [24]. Northern
blotting analysis of bovine brain capillary total RNA [25]
and rat brain poly(A+) mRNA [26] demonstrates a
characteristic 2.8-kb band corresponding to the GLUT1
transcript, and GLUT1 mRNA is not detected in bovine
and rat brain which has been depleted of vascular
elements [25,26]. These observations have lent support
to the hypothesis that GLUT1 is exclusively expressed in
the endothelial cells of the BBB [24,25]. In contrast,
GLUT1 is clearly detectable as a band of 45 kDa on
Western blots of vascular-depleted brain protein, com-
pared to the broad 54-kDa band seen in preparations of
isolated brain capillaries [19,24,27]. The difference in
molecular weight between `vascular' and `non-vascular'
GLUT1 is due to differential glycosylation of the aspargine
residue in the ®rst extracellular loop of the transporter,
with a larger carbohydrate side chain on the vascular form
of GLUT1 [19,24]. Localization of `nonvascular' GLUT1
has been attributed to glial cells: using in situ hybridiza-
tion, Bondy and colleagues have reported in rat brain
sections scattered signals for GLUT1 transcript which
Table 1. Isoforms of the sodium-independent facilitative glucose transporter family and their characteristic tissue localization
GLUT isoform Tissue localization Comments
GLUT1 Human erythrocyte, blood±brain barrier, blood±retinal barriers,
blood±placental barrier, blood±testis barrier
Characteristically expressed in cell types with barrier functions
GLUT2 Liver, pancreatic b-cell Participates in pancreatic glucose sensing
GLUT2 Brain Major transporter in CNS neural tissue
GLUT4 Fat, skeletal muscle, myocardial tissue Insulin-sensitive
GLUT5 Intestinal epithelium Fructose transporter
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appear to localize to astrocytes [28], and in recent
studies, McCall and co-workers have reported speci®c
staining for GLUT1 in the parenchyma of normal rat
brains which colocalizes with glial ®billary acidic protein
(GFAP), a speci®c marker of cells of glial origin [29].
Furthermore, Yu and co-workers have demonstrated
GLUT1 immunoreactivity in rat brain glia and oligoden-
drocytes by electron microscopic immunohistochemistry
[30]. Additional, indirect evidence of GLUT1 in brain glial
cells is the abundant expression of GLUT1 protein and
transcript in primary cultures of rat brain glial cells [31].
These latter data, however, must be interpreted with
caution, since GLUT1 may be expressed in most cells in
culture, even in cell types which do not express the
protein in vivo [6]. Nonetheless, evidence from cytocha-
lasin-B binding assays [32] and immunohistochemical
[24,29] and in situ hybridization studies [24,28] suggest
that GLUT1 is predominantly expressed on the BBB.
At a subcellular level, GLUT1 is localized to both the
luminal and abluminal membranes of the endothelial cells
of the rat BBB, and approximately 40% of total cellular
GLUT1 in the rat BBB resides in the cytosol [33]. An
asymmetrical distribution of GLUT1 between the luminal
and abluminal membranes of the rat BBB has been
documented, in which the ratio of luminal to abluminal
transporters is approximately 1 : 4 [33], an observation
which suggests that glucose transport at the BBB is limited
at the lumenal membrane. This pattern of asymmetrical
distribution has been reported in the BBB of the
developing rabbit as well [34]. Taken together, these
data suggest that the lumenal membrane of the endothe-
lial cells represents a critical interface for glucose entry
into brain: BBB glucose transport may be upregulated by
either increased expression of GLUT1 or, in a more acute
setting, by translocation of pre-existing cytosolic trans-
porters to the lumenal membrane [34].
As mentioned above, GLUT3 has been identi®ed as the
principal glucose transporter isoform in neural cells in
brain. Gerhart and co-workers have used an antiserum
directed against the carboxyl terminus of human GLUT3
to report the presence of GLUT3 in the canine BBB as well
[35]; however, this observation has been challenged by
others [27], who cite a lack of speci®city between human
and canine carboxyl terminus amino acid sequences of
this transporter isoform. Based on numerous studies, a
consensus has emerged that in the brain, GLUT3 is
localized to the neuropil [27,36,37]. With regard to
expression of other glucose transporter isoforms on the
microvasculature of the brain, studies from other
laboratories have reported the apparent localization of
GLUT2 in the hypothalamus [38], and the insulin-
sensitive transporter, GLUT4, in the BBB of the frontal
cortex [39]. The presence of the latter isoform ± albeit, at
very low abundance ± on the BBB is intriguing, since
glucose uptake by the brain is thought to be insulin-
insensitive [1]. BBB expression of GLUT5, the fructose
transporter [40], and of a sodium-dependent glucose co-
transporter similar to SGLT2 [41] have also been
reported. Nonetheless, the extremely close agreement
between the density of D-glucose-displaceable cytochala-
sin-B binding sites and immunoreactive GLUT1 abun-
dance on isolated brain capillary preparations [42]
provides evidence that glucose transport across the BBB
is predominantly mediated by GLUT1.
Although glucose transport into whole brain has been
extensively studied in both animal models [26,43±45]
and human subjects [46], it is clear that there is a great
deal of heterogeneity in brain glucose uptake and
utilization in different brain regions [47±50]. Glucose
transporter gene expression in the brain also demon-
strates regional variation [51,52]. For example, GLUT1 is
expressed in higher density in gray matter than white
matter, and its expression is positively correlated with
regional glucose utilization [52]. GLUT3 expression
shows regional heterogeneity; however, unlike GLUT1,
there is no correlation with regional glucose consumption
[53]. Western blotting studies by Brant and co-workers
using isoform-speci®c antisera demonstrate that GLUT2 is
expressed at low levels throughout the rat brain, with the
highest levels in the optic chiasm and pituitary. In
contrast, GLUT4 expression is predominantly limited to
the pituitary, hypothalamus and cerebellum [51]. (The
apparent contradiction between an inability to detect
GLUT4 in frontal cortex by Western blotting by Brant et al.
[51] and the presence of GLUT4 in microvessel prepara-
tions reported by McCall et al. [39] may be explained by
the extremely low abundance of GLUT4, in comparison to
that of GLUT1, in the frontal cortex [39].)
Regulation of glucose transporter
expression in brain
In the brain, GLUT1 expression is subject to develop-
mental regulation with a decrease in immunoreactive
GLUT1 in the immediate postnatal period, followed by a
gradual increase in localization of GLUT1 to the BBB and
an increase in its abundance to levels comparable to those
in adults by 30±60 days after birth [42,54,55]. The
gradual increase in BBB GLUT1 expression and decrease
in parenchymal (i.e. nonvascular) GLUT1 correlate with
the maturation of the BBB in the rat brain [56]. The
neuronal glucose transporter GLUT3 also undergoes
developmental regulation, which coincides with neuronal
maturation [57].
In studies using bovine brain endothelial cell cultures,
an in vitro model of the BBB, GLUT1 mRNA expression
has been shown to be upregulated in response to glucose
deprivation [58,59], phorbol esters and serum [60] and
growth factors, including tumor necrosis factor-a (TNF-a)
[61], brain-derived peptides [62] and glial-derived
factors [63,64]. Of note, GLUT1-mediated glucose trans-
port in brain capillary endothelial cells is not affected by
insulin [65], an observation which supports the concept
that BBB glucose transport is insulin-insensitive [1].
Upregulation of brain microvascular endothelial GLUT1
abundance in response to glucose deprivation appears to
be regulated at a post-transcriptional level, since nuclear
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run-on assays of bovine brain endothelial cells grown in
media at low glucose concentrations demonstrate tran-
scription rates which are similar to that of controls [59].
Actinomycin D studies of these cell cultures reveal a
prolongation of the half-life of the GLUT1 transcript in
glucose-deprived cell cultures, suggesting that the
increase in GLUT1 mRNA (and by inference, in immu-
noreactive GLUT1 protein) during glucose deprivation
occurs via stabilization of the GLUT1 transcript [59].
In animal models, BBB glucose transport and/or
GLUT1 abundance has been shown to be modulated
by streptozotocin-induced diabetes [44,45,66], chronic
hypoglycemia [26,67±69], localized cerebral ischemia
[29,70±72] and seizures [73,74]. In human brain
samples, GLUT1 abundance has been reported to be
decreased in the neocortex and hippocampus in Alzhei-
mer's disease [75], and GLUT1 and GLUT3 have been
reported to be decreased in the caudate and putamen in
Huntington's disease [76]. Astrocytoma, a central nervous
system tumor of glial cell origin, demonstrates an increase
in GLUT1 and GLUT3 mRNA with increasing grade
of malignancy; however, only immunoreactive GLUT3
protein is detected in the highest grade gliomas
[77,78]. An absence of GLUT1 protein despite a relative
high abundance of GLUT1 mRNA in high-grade gliomas
has been explained by post-transcriptional modi®cation
of the GLUT1 mRNA: a 48-kDa cytosolic protein which is
overexpressed in high-grade gliomas acts in trans to bind
to speci®c sequences within the 3k untranslated region
(3k UTR) of the GLUT1 mRNA. This interaction appar-
ently results in destabilization of the GLUT1 transcript
and gives rise to a discordance between the abund-
ance of GLUT1 mRNA and immunoreactive protein [79].
Glucose transport and glucose transporter gene expres-
sion may be upregulated in situations of physiological
stress to compensate for increased metabolic demand.
Experimental brain ischemia produced by middle carotid
artery occlusion results in upregulation of GLUT1
transcript both at the BBB and in brain parenchyma
[70,71], a change which apparently is associated with a
similar upregulation in GLUT1 protein [29]. The protec-
tive role of GLUT1 upregulation in brain has been
observed in studies using replication-defective herpes
simplex viral vectors to induce GLUT1 overexpression in
neurons in vitro and in vivo: GLUT1 overexpression
protects cultured neuronal cells against hypoxia-induced
necrosis [80] and protects hippocampal neurons against
ischemic injury and death in a rat model of stroke [81].
Compensatory increase of GLUT1 abundance on the BBB
has been reported in a resected seizure focus of human
brain [73], and upregulation of brain GLUT1 and GLUT3
have been reported in an animal model of chronic
seizures [74]. The critical role of GLUT1-mediated BBB
glucose transport in the provision of substrate to the brain
is also evidenced by the report of seizures, developmental
delay and hypoglycorrachia (low cerebrospinal ¯uid
glucose concentrations) in two infants with a haploinsuf-
®ciency of GLUT1 [82].
Downregulation of glucose transport into brain has
been reported in streptozotocin- and alloxan-induced as
well as spontaneous diabetes in rats [44,45,66,83], a
change that is secondary to a decrease in glucose
transporter density at the BBB [45,84]. This decrease in
BBB glucose transport and the consequent relative
neuroglycopenia have been proposed as the basis for
the neuroglycopenic symptoms experienced at normogly-
cemic levels in some individuals with poorly controlled
diabetes when hyperglycemia is rapidly corrected
[85±87]. The observation of decreased BBB glucose
transport and/or GLUT1 expression in experimental
diabetes, however, has not been universally accepted:
studies from other laboratories have reported either
unchanged or increased BBB glucose transport or GLUT1
density in this setting [69,88±90]. Furthermore, the
concept of decreased cerebral metabolic rates due to a
relative neuroglycopenia in individuals with poorly
controlled diabetes has been called into question.
Increased regional cerebral metabolic rates have been
observed in streptozotocin diabetic rats following acute
normalization of blood glucose levels [91], and more
recently, positron emission tomography has failed to
demonstrate a signi®cant change in brain glucose
metabolism or BBB glucose transport in individuals
with poorly controlled diabetes, compared to non-
diabetic controls [92]. Changes in BBB glucose transport
and GLUT1 expression in the setting of suboptimally
controlled diabetes is the subject of ongoing controversy
[45,69,93].
With regard to changes in BBB GLUT1 in diabetes, an
apparent discordance has been observed between the
abundance of GLUT1 mRNA and protein in the BBB,
similar to that seen in high-grade gliomas: in streptozo-
tocin diabetic rats, BBB glucose transport and GLUT1
protein are downregulated [45], whereas the abundance
of GLUT1 transcript is actually increased [94]. It is
currently not known whether this apparent post-tran-
scriptional modulation of BBB GLUT1 expression is also
due to speci®c RNA-protein interactions such as those
reported in high-grade gliomas [79].
Brain glucose transport in iatrogenic
hypoglycemia
The hope inspired by the results of the Diabetes Control
and Complications Trial (DCCT) [95] ± that intensive
insulin therapy with near-normalization of blood glucose
levels leads to dramatic reductions in the risk of
development and progression of microvascular complica-
tions ± is tempered by the sobering realization that
intensive insulin therapy is associated with a signi®cant
increase in risk for severe hypoglycemia [96]. Indeed,
iatrogenic hypoglycemia has been referred to as the
`principal obstacle in the treatment of insulin-dependent
diabetes' [97].
Accumulating clinical evidence has suggested that the
increased risk of severe hypoglycemia experienced by
individuals who undergo intensive insulin therapy is due
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to changes in the intricate feedback system which defends
against declining blood glucose levels known as the
counterregulatory response [97±102]. In a non-diabetic
individual, falling blood glucose levels trigger a hierarchy
of hormonal responses, which includes inhibition of
insulin secretion, followed by the sequential release of
glucagon, epinephrine and norepinephrine, cortisol, and
growth hormone [103]. The net result of this crescendo of
hormonal responses is to raise the blood glucose level. In
non-diabetic individuals, the principal defense against
hypoglycemia is production of glucagon from the a-cells
of the pancreas and the resultant stimulation of hepatic
gluconeogenesis [104]. In the setting of insulin-depen-
dent diabetes, however, several defects exist in the
counterregulatory response, including a loss of hypogly-
cemia-stimulated glucagon secretion relatively early in
the course of the disease [105,106]. Consequently,
individuals with Type 1 diabetes mellitus (DM) learn to
depend on autonomic (predominantly adrenergic) `warn-
ing symptoms', including palpitations, tremulousness,
sweating, anxiety and warmth, to know when to seek
carbohydrate replacement [104]. Normally, the counter-
regulatory response ± and its associated autonomic
warning symptoms ± is triggered at a blood glucose
concentration higher than that eliciting neuroglycopenic
symptoms such as confusion, disorientation, stupor, coma
and seizures [103]. The autonomic symptoms thus allow
the individual with Type 1 DM to recognize the
development of hypoglycemia and to seek corrective
measures. Conversely, the loss of autonomic warning
symptoms in the face of declining blood glucose levels
that is associated with an absence or signi®cant impair-
ment of the counterregulatory response is responsible for
the phenomenon of `hypoglycemic unawareness' in which
an individual with Type 1 DM develops cognitive
dysfunction without prior warning symptoms. The
practical consequence of this condition is the inability
of an individual with diabetes to perceive and treat
episodes of hypoglycemia before cognitive impairment
and more severe hypoglycemia occur [107].
An accumulating body of evidence suggests that with
the institution of intensive insulin therapy, the glycemic
threshold for the counterregulatory response shifts to a
lower blood glucose concentration [99,100,108]. Amiel
and co-workers have used insulin clamp studies to
demonstrate that the counterregulatory response in
individuals with well-controlled diabetes, i.e. with
HbA1c values of 7.6t0.7%, is elicited at a lower blood
glucose level than that seen in individuals with poorly
controlled diabetes (HbA1c of 11.5t1.7%) and in non-
diabetic control subjects [99]. Furthermore, institution of
intensive insulin therapy in a subset of the subjects with
poor control is associated with the development of an
identical impairment of counterregulation, like that seen
in the well-controlled group [99]. The stimulus for the
change in the counterregulatory threshold appears to be
the often-unrecognized episodes of intermittent hypogly-
cemia which individuals with Type 1 DM under intensive
insulin therapy experience on a daily basis [109,110].
Impairment of the counterregulatory response due to
intermittent episodes of mild to moderate hypoglycemia
may result in impaired perception of hypoglycemia,
which in turn may act in a vicious cycle in predisposing
an individual with Type 1 DM to further, more severe
hypoglycemia [111]. Individuals in whom warning
symptoms are lost, i.e. those with hypoglycemia unaware-
ness, have an approximately 6-fold increased risk of
severe hypoglycemia compared to individuals with Type 1
DM and an intact warning system [112], and although the
cumulative effects of mild or moderate hypoglycemia on
cognitive function are not certain, recurrent episodes
of severe hypoglycemia are well known to result in
permanent memory loss and cognitive problems [113].
As alluded to in the remarks above, the most vulnerable
organ to the acute and chronic effects of hypoglycemia is
the brain. The absolute reliance of the brain on glucose as
its principal metabolic substrate and the relative lack of
local stores of glycogen underlie the brain's selective
vulnerability to hypoglycemia-mediated injury and its
dependence on glucose transport across the BBB.
Furthermore, under normal physiological conditions,
phosphorylation of glucose within the neuronal cytosol
by hexokinase occurs at a rate approximately half that of
glucose transport and is normally the limiting step in
brain glucose metabolism [1]. In hypoglycemia, however,
brain hexokinase activity decreases out of proportion to
glucose transport, and brain metabolism is limited by BBB
glucose transport. Therefore, in hypoglycemia, GLUT1-
mediated glucose transport at the BBB becomes the
critical component in determining brain metabolism
[22,114].
Experimental evidence has suggested a compensatory
mechanism at the level of the BBB by which the brain
protects itself against hypoglycemic injury. Using three
different means of inducing sustained hypoglycemia in
animals ± repeated injections of long-acting insulin, and
insulin infusion via subcutaneous osmotic pumps and via
implanted insulinomas ± McCall and colleagues demon-
strated an upregulation of brain glucose extraction in
comparison to normoglycemic control animals [67].
Koranyi and co-workers demonstrated an approximate
40% increase in total brain GLUT1 mRNA and protein in a
rat model of sustained hypoglycemia [68]. Subsequent
studies by Kumagai et al. of chronic hypoglycemia in rats
con®rmed McCall's results of increased BBB glucose
transport and demonstrated that this increase was due to
increased abundance of GLUT1 mRNA and protein
speci®cally at the BBB [26]. The compensatory nature
of hypoglycemia-induced changes in BBB glucose trans-
port has been demonstrated in studies comparing the
effects of acute versus chronic hypoglycemia on cerebral
metabolic rate in rats (rCMRgluc) [50]. In contrast to the
reductions seen in glucose transport and rCMRgluc in
acute hypoglycemia, glucose transport is increased, and
rCMRgluc and cortical function (as assessed by somato-
sensory evoked responses) are preserved in chronically
hypoglycemic rats, compared to controls [50]. Taken
together, these data suggest that a compensatory
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upregulation of BBB glucose transport occurs in the
setting of hypoglycemia, and that this increase preserves
brain function in the face of low peripheral glucose levels.
The application of the ®ndings described above to the
understanding of the pathogenesis of the increased risk
for severe hypoglycemia episodes during intensive insulin
therapy must, however, take into account two considera-
tions: the nature of the hypoglycemic stimulus, and the
relationship between brain glucose transport and brain
sensing of hypoglycemia. As mentioned previously, the
type of hypoglycemia experienced by individuals under
intensive insulin therapy is intermittent [109,110] and,
therefore, changes in BBB glucose transport and GLUT1
expression reported in animal models of chronic or
sustained hypoglycemia might not apply in the setting
of intensive insulin therapy of Type 1 DM. Furthermore,
it is unclear whether the changes in counterregulatory
response to hypoglycemia are due to global increases in
BBB glucose transport or to changes in transport in areas
of the brain responsible for detection of declining blood
glucose levels.
Boyle and colleagues recently investigated the relation-
ship between changes in the counterregulatory response
to hypoglycemia, hypoglycemia sensing and BBB glucose
transport in individuals with various degrees of control of
Type 1 DM and in non-diabetic subjects [46]. In a sub-
set of individuals with the most intensively controlled
diabetes (glycosylated Hb of 7.2t0.5%), impairment of
counterregulation and hypoglycemia warning symptoms
were associated with a preservation of BBB glucose
transport. In contrast, individuals with less tightly
controlled Type 1 DM and non-diabetic control subjects
had a decrease in BBB glucose transport in response to the
same hypoglycemic stimulus [46]. The results of this
study suggest that the increased risk of severe hypogly-
cemia observed in intensively controlled Type 1 DM is due
to a compensatory relative increase in total BBB glucose
transport that results in a decreased counterregulatory
response and blunted sensing of hypoglycemia by
individuals under intensive insulin therapy. It is unclear,
however, whether impairment of the counterregulatory
response and hypoglycemia awareness observed in
individuals under intensive insulin therapy are due to
changes in whole brain glucose transport per se, i.e.
whether preserved whole brain BBB glucose transport is
responsible for the impairment in hypoglycemia sensing
in these individuals. In the setting of intermittent
hypoglycemia, the exact relationships between hypogly-
cemia sensing and counterregulatory and cognitive
responses on the one hand, and regional or global
changes in BBB glucose transport on the other, remain to
be elucidated.
With regard to blood glucose sensing, it has long been
hypothesized that the locus of glucose sensing responsible
for the counterregulatory response to hypoglycemia is in
the central nervous system. As demonstrated in canine
studies by Biggers and co-workers, isolated hypoglycemia
of the brain in the presence of systemic euglycemia may
elicit a brisk counterregulatory response; in contrast,
preservation of euglycemia in brain in the presence of
systemic hypoglycemia abolishes the response [115]. In a
series of elegant experiments in rats, Borg and co-workers
provided evidence suggesting that the sensor is situated in
the ventromedial hypothalamus (VMH): induction of
localized, intracellular glycopenia in the VMH of rats
by bilateral perfusion of 2-deoxyglucose into the two
ventromedial hypothalamic nuclei results in a brisk
counterregulatory response in the absence of hypoglyce-
mia [116]. Conversely, perfusion of the VMH with
concentrated glucose solutions abrogates the counter-
regulatory response in the setting of systemic hypoglyce-
mia [117]. Other anatomical sites, including the liver
[118,119], have been proposed as glucose sensing areas
and may play a role in addition to, or in lieu of, the VMH
glucose sensor; nonetheless, the studies cited above
provide ®rm evidence that the primary sensor involved
in counterregulation is localized in the hypothalamus,
and in particular, the VMH [116,117].
The localization of different glucose transporter iso-
forms in the hypothalamus and whether changes occur in
glucose transport and glucose transporter expression in
the setting of intermittent hypoglycemia are unknown at
present. In addition to neuronal GLUT3 and BBB GLUT1,
the presence of the insulin-sensitive GLUT4 has been
reported in the hypothalamus [51]. In a study investigat-
ing extra-pancreatic expression of glucokinase (the
hexokinase isoform involved in glucose sensing in the
b-cell), Jetton and co-workers expressed human growth
hormone (hGH), acting as a reporter gene, in transgenic
mice under the control of a glucokinase promoter [38].
Selective expression of hGH in the ventral hypothalamus
in these studies suggested the possibility of glucokinase
expression in this region of the brain, a ®nding supported
by colocalization of immunoreactive glucokinase and the
GLUT2 glucose transporter in the same region in normal
mice [38]. The ®ndings of Jetton's study are intriguing,
because they suggest that the molecular machinery for
glucose sensing in the b-cell, i.e. GLUT2-mediated glucose
transport coupled with glucokinase activity, is recapitu-
lated in an area of the brain which is responsible for
hypoglycemia sensing. Additional observations, however,
make the identi®cation of the VMH as the `b-cell of the
brain' problematic: GLUT2 expression in the hypothala-
mus localizes to the arcuate nuclei, an area of the
hypothalamus which is adjacent to the VMH [120,121].
GLUT2 and hexokinase, however, have not been reported
in the VMH itself. Furthermore, the presence of the
insulin-sensitive GLUT4 isoform in the hypothalamus
raises the question of whether glucose transport in this
area of the brain is modulated by insulin in addition to, or
instead of, circulating blood glucose levels, a possibility
suggested by 2-deoxyglucose brain autoradiographic
studies in rats [122]. Clari®cation of possible changes
in glucose transport in this critical region in the setting of
intermittent hypoglycemia and the possible role of these
changes in the increased risk of severe hypoglycemia
experienced by individuals during intensive insulin
therapy await further investigation.
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Glucose transport and glucose
transporters in retina
The neuroretina, which is among the most metabolically
active tissues in the body [123], is nourished by transport
of glucose across the endothelial cells of the capillaries of
the inner BRB and from the choroidal vessels across the
retinal pigment epithelium of the outer BRB [2]. Studies
in rats have demonstrated a saturable transport process
for glucose and other hexoses in the retina [124,125];
however, due to the presence of two barriers and due to
uncertainties over the relative contribution of each barrier
to the nourishment of the retina in man, the results of in
vivo studies of glucose transport are dif®cult to interpret
[126]. Studies in isolated bovine retinal capillaries have
shown a sodium- and energy-independent, saturable
transport process for hexoses, with a high af®nity for
the D-stereoisomer of glucose, followed by the analogs
2-deoxy-D-glucose and 3-O-methyl-D-glucose, as well as
D-mannose, D-galactose and D-xylose [127]. In contrast,
L-glucose, ribose and fructose are not transported to any
appreciable extent in these preparations [127]. As in
the endothelial cells of the brain, glucose uptake by ret-
inal endothelia occurs in excess of metabolic rates (i.e.
hexokinase activity), such that a large intracellular pool of
free glucose is present within the endothelial cells [127].
In vivo measurements of retinal glucose transport and
metabolism by NMR spectroscopy have recently con-
®rmed these observations in the rabbit retina: glucose
transport exceeds metabolic rates by approximately 16-
fold [128]. A similar transport process for glucose has
been described in isolated rat and bullfrog retinal pigment
epithelium as well [129,130].
It is now known that the mammalian eye expresses
GLUT1 in a variety of cell types [8,9,131,132]. In the
human eye, GLUT1 is expressed in the retinal capillary
endothelial cells, the retinal pigment epithelium, the non-
pigmented epithelium of the ciliary body, the endothe-
lium of the canal of Schlem, and the capillaries and
posterior pigmented epithelium of the iris [8,131,133]. In
the endothelial cells of the human and rat inner BRB,
GLUT1 is expressed on both the luminal and abluminal
membranes, a critical prerequisite for GLUT1's role in the
transcellular transport of glucose to the neuroretina
[134,135]. Furthermore, in the human inner BRB, a
substantial portion (approximately 50%) of total cellular
GLUT1 resides in cytosolic stores [135]. Because these
transporters are not in contact with the plasma membrane
surface, they are not available for glucose transport;
however, in response to external stimuli, such as growth
factors, these transporters may rapidly translocate to
the plasma membrane where they may participate in
mediating glucose entry into the endothelial cell.
In addition to the endothelial and epithelial cells of the
inner and outer BRB, respectively, GLUT1 is expressed in
cell bodies of the ganglion cell layer, the cell bodies of the
photoreceptor elements and the MuÈller cells, a specialized
glial cell which is oriented radially within the retina
[131,133]. The ®nding of abundant expression of GLUT1
in MuÈller cells is in line with evidence of glucose transport
and metabolism in isolated cell preparations [136] and
supports the hypothesis that this glial cell serves as a
nutrient-supporting cell of the retina [137,138]. In
addition to GLUT1, MuÈller cells have been reported to
express GLUT2, the liver and pancreatic b-cell glucose
transporter, in their foot processes [139]. The selective
function of this transporter in the MuÈller cells, if any, is
currently not known. In the human retina, the expression
of GLUT3 is restricted exclusively to the processes of
neuronal cells of the inner synaptic layer [131], an
observation which supports the role of GLUT3 as the
major neuronal glucose transporter 12]. Immunohisto-
chemical studies have failed to document expression of
the insulin-sensitive glucose transporter, GLUT4, and the
fructose transporter, GLUT5, in the retina of the human
eye [131].
Regulation of glucose transporter
expression in retina
The factors mediating glucose transport and glucose
transporter expression are not as well de®ned in the
retina as they are in the brain. Expression of GLUT1 in the
various cell types within the retina is preserved during
development and is evident as early as 8 weeks of
gestation [131]. In contrast, GLUT3 is not detected in the
neuroretina in the fetus and localizes to the inner synaptic
layer only in the adult retina [131]. As in other tissues,
glucose transport and/or GLUT1 expression is modulated
by hypoxia, growth factors and glucose in primary
cultures of retinal endothelial cells, a cell culture model
of the inner BRB [140,141] (A.K.K., in preparation).
In cultured human retinal pigment epithelial cells,
2-deoxyglucose uptake and GLUT1 transcript have been
shown to be upregulated in response to serum, insulin-
like growth factor-1 (IGF-1), basic ®broblast growth
factor (bFGF), platelet-derived growth factor (PDGF),
and epidermal growth factor (EGF) [142].
Inner blood retinal barrier glucose
transport in retinopathy
Diabetic retinopathy is one of the principal microvascular
complications of long-standing diabetes mellitus and
represents the leading cause of blindness in working
age adults in the USA [143,144]. Pathologically, the
characteristic lesions and changes associated with dia-
betic retinopathy are localized to the retinal microvascu-
lature of the inner BRB. These changes include loss of
pericytes, increased tortuosity of retinal capillaries,
formation of microaneuryms, leakage of plasma proteins,
capillary obliteration, and, in the most severe stages of
diabetic retinopathy, neovascularization [143]. The
metabolic `culprit' behind these changes appears to be
chronic exposure of the retina to the hyperglycemia
Glucose Transporters in Brain and Retina 267
Copyright # 1999 John Wiley & Sons, Ltd. Diabetes Metab Res Rev 1999; 15: 261±273.
associated with long-standing diabetes, a proposition
which rests on two major lines of clinical evidence: ®rst,
the severity of retinopathy is correlated with poor
glycemic control [145], and conversely, as demonstrated
by the landmark DCCT, near-normalization of blood
glucose levels prevents or delays the progression of
diabetic retinopathy in individuals with Type 1 DM [95].
The exact biochemical and molecular mechanisms that
transduce the chronic hyperglycemia of diabetes into
pathological changes in the retina have yet to be fully
clari®ed. Attention has focused on the role of several
pathways in this process, including oxidative stress,
activation of protein kinase C (PKC), non-enzymatic
glycation and direct toxic effects of glucose on endothelial
function, replication and survival [146,147]. A common
denominator, however, which connects hyperglycemia
with these pathways is the exposure of the intracellular
milieu of the retinal capillary endothelial cell to elevated
blood glucose concentrations. Indeed, increased retinal
endothelial cell glucose ¯ux is assumed in the con-
ceptualization of several of these pathways (Figure 1)
[147,148].
As mentioned previously, glucose may gain entry into
the endothelial cells of the inner BRB only via transport
mediated by GLUT1 [2]. Furthermore, GLUT1-mediated
transport operates at near-saturation levels at normal
physiological blood glucose concentrations [6]. There-
fore, elevations in blood glucose levels, such as those seen
in diabetes mellitus, will have only a minor impact in
increasing intracellular glucose concentrations. Because
GLUT1 represents a unique portal of entry of glucose into
the endothelial cells of the inner BRB, changes in retinal
endothelial cell GLUT1 expression and glucose transport
may have a major impact in providing substrate to the
various pathogenic processes thought to underlie the
development of diabetic retinopathy (Figure 1).
In a previous study, Kumagai and co-workers used
immunogold electron microscopy to demonstrate loca-
lized upregulation of GLUT1 in retinal endothelial cells of
postmortem retina specimens from three individuals with
long-standing diabetes but without clinical evidence of
diabetic retinopathy (Figure 2) [135]. On the lumenal
surface of the affected endothelia, there was a 20-fold
increase in immunoreactive GLUT1, compared to micro-
vessel pro®les from non-diabetic retinas [135]. The
upregulation of inner BRB GLUT1 was not uniform in
the diabetic microvessels, but appeared to be localized,
i.e. only certain capillaries exhibited increased GLUT1
abundance, while in other microvessels, GLUT1 abun-
dance was not signi®cantly different from that seen in
non-diabetic specimens. The focal nature of the changes
in GLUT1 expression in the diabetic inner BRB observed
in this study is reminiscent of the focal histopathological
changes and areas of inner BRB compromise which occur
in the retinal microvasculature in diabetic retinopathy
[143,149]. Upregulation of total retinal GLUT1 mRNA
has been reported in galactosemic rats, which develop
hyperhexosemia and retinal lesions similar to those seen
in human diabetic retinopathy [150], and GLUT1 mRNA
abundance has been reported to be increased in the retina
of streptozotocin-induced diabetic rats, albeit to a
level which was not statistically signi®cant [151]. Taken
together, these studies suggest that upregulation of
retinal and, in particular, inner BRB GLUT1 occurs in
the early stages of diabetic retinopathy, and that the
resultant increase in inner BRB glucose transport plays a
role in the progression of the pathological changes seen in
later stages of the disease.
Figure 1. Proposed role of inner blood±retinal barrier GLUT1
in the development of microvascular pathology in diabetic
retinopathy
Figure 2. GLUT1 immunogold electron microscopy of non-
diabetic and diabetic inner blood±retinal barrier. (A) Non-
diabetic retinal endothelial cell labeled with a 1 : 800 dilution
of anti-GLUT1 antiserum, followed by 10 nm colloid gold-
conjugated IgG. Sections were counterstained with uranyl
acetate. GLUT1 immunogold is represented by discrete black
dots along the lumenal or ablumenal membranes or scat-
tered in the cytoplasm of the endothelial cell. Bar=0.20 mm.
(B) Representative endothelial cell from subpopulation of
diabetic microvessels demonstrating dramatically increased
GLUT1 expression. L, capillary lumen; N, nucleus of endothe-
lial cell. Bar=0.22 mm. Modi®ed from Kumagai et al. [135].
Used with permission of Elsevier Science
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In order to understand the role which changes in inner
BRB GLUT1 expression may play in the pathogenesis of
diabetic retinopathy, studies of the effects of different
factors associated with the development of diabetic
retinopathy on inner BRB glucose transport and GLUT1
expression are needed. In a recent publication, Takagi
and colleagues demonstrated upregulation of GLUT1
transcript and protein in primary cultures of bovine
retinal endothelial cells exposed to hypoxia [140]. The
hypoxic conditions (0.5% O2) increased GLUT1 mRNA by
approximately 9-fold and GLUT1 protein and 2-deoxy-
glucose transport by 2.5- and 3-fold, respectively, after
12 h. These changes were partially mimicked by A2
adenosine receptor agonists and partially inhibited by A2
receptor antagonists. Furthermore, an inhibitor of protein
kinase A (PKA) partially abolished the hypoxia-mediated
increase in GLUT1 mRNA abundance. These experiments
demonstrate that hypoxia can upregulate GLUT1 expres-
sion and glucose transport in vitro, and that this process
occurs through an adenosine-A2 receptor-PKA pathway
[140]. While hypoxia ± a factor associated with advanced
non-proliferative diabetic retinopathy ± provides a potent
stimulus for increases in GLUT1 expression in retinal
endothelial cells [140], growth factors or other metabolic
perturbations (e.g. oxidative stress, increased PKC
activity) present early in the development of diabetic
retinopathy may play a role in modulating inner BRB
GLUT1. Studies from the author's laboratory have
demonstrated an enhancement of glucose transport in
primary bovine retinal endothelial cell cultures by
vascular endothelial growth factor (VEGF) (A.K.K., in
preparation). VEGF, a cytokine that selectively acts on
endothelial cells to increase vascular permeability and
stimulate angiogenesis [152], has been demonstrated to
play a major role in the development of proliferative
retinopathy [153±155]. Although there is some con-
troversy [156], numerous studies in humans [157,158]
and animal models [159,160] suggest that VEGF may
play a role in the non-proliferative stage of the disease as
well.
With regard to the direct effects of glucose on retinal
vascular cell glucose transport, Mandarino and colleagues
have reported that exposure to elevated glucose concen-
trations for 5 days downregulates both glucose transport
and GLUT1 mRNA and protein in primary cultures of
retinal pericytes, but has no effect on glucose transport
retinal endothelial cells [141]. Changes in endothelial
expression of GLUT1 transcript or protein were not
investigated in this study. Knott and co-workers have
reported upregulation of GLUT1 and GLUT3 mRNA in
response to elevated glucose concentrations in human
retinal endothelial cell cultures [161]. The observations
of Knott and co-workers with respect to glucose-mediated
changes in cultured retinal endothelial cell GLUT3
expression, however, are dif®cult to interpret, since
immunoreactive GLUT3 is not detected in plasma
membranes of cultured retinal endothelial cells [141],
and more crucially, GLUT3 is not present in the retinal
endothelial cells of the inner BRB in vivo [131].
A possible role of upregulated GLUT1 expression in the
pathogenesis of diabetic complications is not unique for
the retina. In a cell culture model of renal mesangial cells,
another cell type which is selectively vulnerable to the
effects of long-standing hyperglycemia, Heilig and co-
workers induced mesangial cell GLUT1 overexpression
via retroviral-mediated transfection. The investigators
observed increased intracellular concentrations of sorbi-
tol and myo-inositol and accumulation of extracellular
matrix components in the GLUT1-overexpressing cultures
grown in normal glucose when compared to lacZ
transfected controls [162]. In other words, in mesangial
cells in culture, overexpression of GLUT1 recapitulates at
least some of the phenotypic characteristics of the diabetic
milieu. While mesangial cells in culture differ from
cultured retinal endothelium in that mesangial cell
GLUT1 is positively regulated by glucose [163], factors
associated with the diabetic milieu in the retina, such as
localized hypoxia and growth factor expression, may
serve as the initial impetus for GLUT1 upregulation and
thus expose the endothelial cells of the retina to elevated
intracellular glucose concentrations. In this manner,
localized upregulation of inner BRB GLUT1 expression
may exacerbate the deleterious effects of hyperglycemia
on the retinal microvasculature and play a critical role in
the development and progression of diabetic retinopathy.
Conclusions
Facilitated transport of glucose across the continuous
endothelium comprising the BBB and inner BRB ensures
continual delivery of this essential metabolite into the
brain and retina, respectively. As described above, this
transport process, and the glucose transporter that
mediates it, may be modulated by a variety of factors,
including hypoxia, growth factors, physiologic stress and
glucose itself. Changes in endothelial glucose transport
and in the abundance of GLUT1 on the endothelial
plasma membrane in these barriers may have profound
consequences in glucose delivery to neural tissue and
may be intimately connected with the development of
complications associated with diabetes mellitus and its
treatment. In the brain, hypoglycemia-associated com-
pensatory upregulation of BBB glucose transport may
preserve BBB glucose transport and brain glucose
metabolism in the face of low peripheral blood glucose
concentrations. The ultimate consequence of this
increase, however, may be deleterious: changes in brain
glucose transport in the setting of intensive insulin
therapy may result in a blunting of the counterregulatory
response to hypoglycemia, a decreased awareness of
autonomic warning symptoms, and a substantially
increased risk of further, more severe hypoglycemic
episodes. In the retina, increased abundance of GLUT1
on the plasma membranes of retinal capillary endothelial
cells resulting from exposure to various factors associated
with the development of diabetic retinopathy (e.g.
hypoxia, growth factors) may lead to increased glucose
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transport into the endothelial cells (Figure 1). This
increased in¯ux, and the subsequent increase in intra-
cellular glucose concentrations, may exacerbate the
effects of hyperglycemia on the endothelial cell, in
effect by `adding fuel to the ®re' of the various
biochemical and molecular processes leading to the
development of the characteristic structural and func-
tional changes in the inner BRB associated with diabetic
retinopathy. The studies described above suggest the
critical importance of BBB glucose transport to changes in
brain glucose sensing and to the increased risk of severe
hypoglycemia experienced by individuals attempting to
achieve optimal glycemic control. With regards to diabetic
retinopathy, a paradigm is proposed in which changes in
glucose transport in the endothelia of the inner BRB
participate in the development of the microvascular
lesions in the retina in long-standing diabetes mellitus.
Clari®cation of the exact role of changes in BBB and inner
BRB glucose transport and glucose transporter expres-
sion, and the molecular processes underlying such
changes, in these complications of diabetes are the
subject of ongoing investigation.
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